BPC-157 Monitoring for Adults Ages 50 to 64: What Clinicians and Patients Need to Know
HealthRX.com
No monitoring schedule exists yet for older adults
See the public record for BPC-157
At a glance
- Approval status / Not FDA-approved; no approved product found in any country FDA searched [1]
- Human safety data / FDA: insufficient clinical safety information to characterize the safety profile [1]
- Human pharmacokinetics / None found for oral, subcutaneous, nasal or skin use [1]
- Checked in a human study / Blood work and vital signs before and after each infusion, repeated on following days, in 2 adults aged 58 and 68 [3]
- Animal signals / aPTT, ALT, glucose and triglycerides shifted in 28-day studies [1]
- Sport status / WADA S0, prohibited at all times [4]
What was measured in people
In a two-person intravenous study, researchers took baseline blood work and vital signs, infused 10 mg of BPC-157 on day 1 and 20 mg on day 2, then repeated fasting blood work and vital signs on the following days. One participant was a 58-year-old man and the other a 68-year-old woman [3]. The tested heart, liver, kidney, thyroid and glucose markers showed no measurable change, and no side effects were reported [3]. Two people cannot support a safety conclusion.
A single-arm pilot injected a total of 10 mg around the bladder wall in 12 women aged 39 to 76 whose interstitial cystitis had not responded to pentosan polysulfate; 10 of 12 reported complete symptom resolution and 2 of 12 about 80%, with no adverse events reported [5]. A retrospective chart review at one Florida clinic included 17 patients given BPC-157 into the knee, alone or with thymosin beta-4 (16 were reached by phone); 11 of 12 who received BPC-157 alone reported significant improvement, with no control group and no validated outcome tools [6].
None of these studies [3][5][6] sets a monitoring schedule for adults ages 50 to 64, and the systematic review concluded BPC-157 should not be used clinically outside ethically approved, regulated, high-quality trials [2].
Questions worth asking
What the animal studies showed
In 28-day intramuscular toxicity studies, BPC-157 shortened clotting time (aPTT) in rats and prolonged it in dogs, and raised liver enzyme (ALT), glucose and triglyceride levels [1]. Longer studies and cancer-risk studies were not available [1]. FDA also noted that the reported protective effects, such as preventing colonic fistulas and liver or gut lesions, come from rat studies rather than human trials, that the molecular targets have not been identified, and that dose-response relationships for those effects were not established [1].
What has been reported as harm in people
FDA's search of its adverse-event database through December 4, 2025 found 3 reports, all for injectable BPC-157: injection-site redness and swelling lasting 9 days in a patient who also used a compounded thymosin product; shortness of breath leading to an emergency room visit; and widespread skin and gum darkening that recurred on re-exposure to a BPC-157 plus TB-500 research product [1]. FDA said it cannot tell whether BPC-157 caused any of them [1].
In the small human studies FDA reviewed, no serious adverse events were reported, but the studies were short and small; in the healthy-volunteer enema studies the most frequent events were headache and flatulence [1]. FDA concluded there is insufficient clinical safety information to characterize the safety profile, and found no human studies of BPC-157 given by mouth, by subcutaneous injection, as a nasal spray or on the skin [1].
What is its regulatory status?
FDA's July 2026 review found no approved product containing BPC-157 in any country it searched, and its reviewers recommended against adding it to the pharmacy bulks list [1]. A July 23, 2026 advisory committee vote favoring its addition is advice only; BPC-157 is not on the list [7][8]. A draft HHS enforcement-discretion policy announced October 28, 2026 is not an approval and does not put BPC-157 on any list [9]. WADA names BPC-157 in S0, prohibited at all times [4].
Check what you know
Question 1 of 3
Score: 0 right, 0 of 3 answered
Frequently asked questions
What has been checked in people given BPC-157 at around age 55?
Is BPC-157 FDA-approved for anything?
Could BPC-157 interact with a statin or a blood thinner?
Is BPC-157 allowed in sport?
References
Show all 9 referencesHide references
- U.S. Food and Drug Administration.
- Poolton JT, Minett J, Kazmi A. Human evidence for BPC-157 in orthopaedic and regenerative medicine: a systematic review of efficacy and safety. Acta Orthop Belg. 2026.
- Lee E, Burgess K. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Altern Ther Health Med. 2025.
- World Anti-Doping Agency.
- Lee E, Walker C, Ayadi B. Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study. Altern Ther Health Med. 2024;30(10):12-17.
- Lee E, Padgett B. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Altern Ther Health Med. 2021;27(4):8-13.
- U.S. Food and Drug Administration.
- Official web page.
- Official web page.